A Phase I Randomized Placebo-controlled Double-blind Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QuantiFERON-TB Gold (+) and QuantiFERON-TB Gold (-) Adults Without Evidence of Tuberculosis.

Trial Profile

A Phase I Randomized Placebo-controlled Double-blind Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QuantiFERON-TB Gold (+) and QuantiFERON-TB Gold (-) Adults Without Evidence of Tuberculosis.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2016

At a glance

  • Drugs Tuberculosis vaccine (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions
  • Sponsors Aeras; Crucell
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Mar 2016 Results (n=20) published in the Vaccine.
    • 02 May 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top